SBIR/STTR Research Award

Gene delivery into whole, adult, large animals

Award identifier 143505813d6b771f6fb90f62ea9e59418c340cac6720f4e475d807a06e524baaAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$93,400

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TOSK, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
M5DLPCVDRE95
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The long term goals for this work is to determine whether our gene delivery vector technologies are efficient and safe for creating large transgenic animals, specifically chickens, pigs, and goats. This project is the next step in testing these new gene delivery vectors on their way for use in human gene therapy. However, success in the large animals in this project would yield immediate opportunities in the therapeutic protein production, agriculture improvement, and disease model creation markets. The Stealth Gene and Targeted Gene Delivery (TGD) vector technologies enable high efficiency gene delivery into whole, adult animals. Both integrate the delivered DNA directly into the genome with Stealth Gene being random and TGD being targeted via homologous recombination. The integration frequency is 5 to 10-fold higher using Stealth Gene over TGD. However, for human gene therapy applications the lower efficiency may be outweighed by the better safety profile associated with targeted, homologous gene delivery. Both of these vectors show extraordinary results in small animals such as mice and rats. Based on these observations, this project is to test whether these gene delivery vectors will work in large animals that have huge commercial value and is the next step for human clinical applications. Specifically, we will examine the vector's ability to deliver an exogenous gene into the epidermis, reproductive tissues, and milk producing tissues. The integration frequency of the marker gene and its expression will be examined. The results of these experiments will be assessed using standard techniques at the molecular and cellular levels. These results will be the basis for deciding whether this technology shows promise to expand testing in large animals and eventually begin testing in people.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

5 SBIR/STTR records share this UEI (2003–2017). Reported award amounts total $2,613,587. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.